AEON Biopharma

AEON · NASDAQ

$0.2315+$0.0005 (+0.22%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $0.231

AEON analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $1.81 (+682.1% upside)

Low: $1.21
Now: $0.2315
High: $2.20

Upgrades and downgrades

The latest rating actions, newest first

AEON analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Lake Street	Oct 1, 2026	Maintains	Buy	$1.00 → $2.00	27%
HC Wainwright & Co.	Aug 14, 2026	Maintains	Buy	$5.00 → $1.20	50%
Lake Street	Jul 30, 2026	Initiates	Buy	$1.00	27%

The case for and against

Updated Feb 1, 2025

Bull case

AEON Biopharma has achieved notable milestones, including obtaining regulatory approvals for its botulinum toxin complex ABP-450 in India and Mexico, which positions the company favorably within the international healthcare market. A significant gain of $161.2 million related to changes in the fair value of contingent consideration liabilities underscores the company's strong financial maneuvering and management efficiency. Additionally, successful alignment with the FDA on biosimilar pathway requirements suggests a reduced risk for clinical studies, enhancing the potential for ABP-450's successful market entry and supporting a positive long-term outlook for the company.

Bear case

AEON Biopharma Inc. experienced significant declines in both research and development (R&D) and general and administrative (G&A) expenses, with R&D expenditures dropping 50.8% year-over-year to $4.4 million, indicating potentially reduced investment in critical clinical development. The company reported a loss per share of $0.11 for the second quarter of 2023, highlighting ongoing financial challenges. Additionally, fundamental risks include reliance on a single, unapproved product, potential failure in clinical trials, competition from larger firms, dependency on a third-party manufacturer, and the necessity for further funding, which collectively contribute to a negative outlook for the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.